Reports

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Acute Bacterial Skin and Skin Structure Infections Treatment Market Size, Share: By Infection Type: Hospital Acquired, Community-acquired, Others; By Route of Administration: Oral, Parenteral, Topical, Others; By Treatment Channel; Regional Analysis; Current Scenario Evaluation; Challenges & Unmet Needs; Supplier Landscape; 2023-2031

Global Acute Bacterial Skin and Skin Structure Infections Treatment Market Report

The acute bacterial skin and skin structure infections treatment market is driven by the growing incidence of skin and skin structure infections. Rising research and developmental activities by pharmaceutical companies and expanding drug pipelines are anticipated to facilitate market growth during the forecast period.

 

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Treatment Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Company News:

In June 2022, Basilea Pharmaceutics attained the permission to apply for the approval of its new antibiotic Ceftobiprole. Basilea will apply for approval on the basis of the results of its TARGET study. This drug, once approved, will be in the acute bacterial skin and skin structure infections treatment market.

 

In December 2021, Nuzyra, an innovative drug, was approved by China’s NMPA for treating patients with ABSSSIs. It is believed to act on a wide range of pathogens responsible for chronic infections. This will also help in the complete treatment at home, thus saving the patient costs.

 

In July 2021, the FDA also approved Dalvance, a synthetic glycopeptide which will now help treat ABSSSIs in children. It was earlier only approved for adults.

 

Introduction of the Acute Bacterial Skin and Skin Structure Infections Treatment Market

Acute bacterial skin and skin structure infections (ABSSSIs) are chronic skin infections with at least one significant lesion size. These infections are generally associated with skin and soft tissues. These acute bacterial skin and skin infections are of two types- complicated and uncomplicated acute bacterial skin and skin infections.

 

Types of Acute Bacterial Skin and Skin Structure Infections

As the name suggests, complicated infections affect the deeper soft tissue and thus require surgical procedures as a treatment. The causative agents for uncomplicated infections are Streptococcus pyogenes and Staphylococcus aureus. The complicated acute bacterial skin and skin structure infections typically include burns, ulcers, and primary abscesses, while uncomplicated ones include furuncles, superficial abscesses, impetiginous lesions, and cellulitis.

 

Diagnostic Tools for ABSSSIs 

Standard laboratory tests, radiological examinations, and microbiological examinations are often used to diagnose these infections. The treatment for acute bacterial skin and skin structure infections is speculative and depends on the prevalent signs and symptoms and the type of affected location. A broad spectrum of antibiotics is often prescribed, and the patient is monitored for the entire course duration. Antibiotic therapy must be defined based on the type of the pathogen involved and the varied clinical spectrum of disease.

 

Out of all the prevailing infections, community-associated methicillin-resistant Staphylococcus aureus accounts for the maximum share in the acute bacterial skin and skin structure infections treatment market. The maximum incidence rate of acute bacterial skin and skin structure infections is witnessed in the United States.

 

According to the acute bacterial skin and skin structure infections market research report, the market can be categorised into the following segments:

 

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Treatment Market By Infection Type

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Breakup by Infection Type 

  • Hospital Acquired ABSSI
  • Community Acquired ABSSI
  • Others

 

Market Breakup by Route of Administration 

  • Oral
  • Parenteral
  • Topical
  • Others

 

Market Breakup by Treatment Channel 

  • Public
  • Private

 

Market Breakup by Region

  • North America

United States of America

Canada

  • Europe

United Kingdom

Germany

France

Italy

Others

  • Asia Pacific

China

Japan

India

ASEAN

Australia

Others

  • Latin America

Brazil

Argentina

Mexico

Others

  • Middle East and Africa

Saudi Arabia

United Arab Emirates

Nigeria

South Africa

Others

 

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Treatment Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Acute Bacterial Skin and Skin Structure Infections Treatment Market Outlook

The acute bacterial skin and skin structure infections treatment market is driven by the rising number of plaque psoriasis diagnosed cases, which was nearly 125 million in 2021. The prevalence of plaque psoriasis disease is likely to grow at a rate of 21% in the forecast period of 2023-2031 and reach approximately 692 million by 2030.

 

The growth of the market is also facilitated by the rising incidence of skin and skin structure infections. Skin diseases are among the most prevalent issues experienced by people, affecting about one-third of the global population. Skin diseases account for nearly 1.79% of the worldwide burden of diseases.

 

According to the 2022 Pubmed statistics, 94 million Europeans complain of skin infections, thus indirectly contributing to a significant share of the market.

 

The most common causative pathogen for acute bacterial skin and skin structure infections is S. Aureus and streptococci, among other gram-positive bacteria. North America and the Asia Pacific account for the maximum share of the acute bacterial skin and skin structure infections treatment market. Based on gender, acute bacterial skin and skin structure infections are more prevalent in men than women.

 

The key factors contributing to the acute bacterial skin and skin structure infections treatment market growth include increased prevalence rate, increased awareness among communities, advanced research and development activities and increased clinical trials.

 

There are several limiting factors which hinder the market expansion. Strict regulatory policies by authorities, termination of the patent license, and antibiotic resistance for various strains hamper the market’s overall development.

 

The COVID-19 pandemic also worsened the symptoms and condition of acute bacterial skin and skin structure infections in patients and thus, leading to prolonged hospitalisation and treatment. Apart from that, the pandemic also affected the drug and pharmaceuticals’ global supply, thus significantly impacting the treatment market share.

 

Henceforth, the novel product inventions for treatment by pharmaceutical and biotechnological companies are the key factors driving the market forecast.

 

North America Accounts for the Maximum Share of the Acute Bacterial Skin and Skin Structure Infections Treatment Market

The United States of America is one of the leading disease treatment markets, accounting for the maximum number of acute skin and skin structure infections globally. In the United States, around 3.3 million patients experienced acute bacterial skin and skin structure infections, leading to an increase in ambulatory care and emergency department visits by 30% and 40%, respectively.  This directly leads to the manifold increase in the acute bacterial skin and skin structure infections treatment market.

 

Therapeutic Landscape

Acute bacterial skin and skin infections are chronic skin infections affecting the skin and soft tissues. The treatment and management are based on the guidelines published by the World Health Organisation. According to these guidelines, acute bacterial skin and skin infections are divided into two categories: Purulent and Non-Purulent.

 

Non-purulent acute bacterial skin and skin structure infections include erysipelas and cellulitis, while purulent acute bacterial skin and skin structure infections include abscesses. The different antibiotics are prescribed on the basis and type of the acute bacterial skin and skin structure infections, which are as follows-

 

  • Severe Purulent Infections: Telavancin, Linezolid, Ceftaroline, Tigecycline, and Vancomycin.
  • Moderate Purulent Infections: Doxycycline and Trimethoprim-Sulfamethoxazole
  • Severe Methicillin-Susceptible S. Aureus Infections: Clindamycin and Cefazolin
  • Moderate Methicillin-Susceptible S. Aureus Infections: Cephalexin and Dicloxacillin
  • Severe Non-Purulent Infections: Vancomycin plus Piperacillin and Vancomycin plus Tazobactam
  • Mild To Moderate Purulent Infections: Clindamycin, Cefazolin, Penicillin, and Ceftriaxone

 

According to the treatment algorithm, the treatment schedule lasts for about 7-10 days. The discovered antibiotics generally target both gram-positive and gram-negative bacteria. These antibiotic formulations can be administered by both parenteral, oral, and topical routes.

 

Marketed Drugs Significantly Contributing to the Market Share

The different categories of antibiotics available in the acute bacterial skin and skin structure infections treatment market are Beta Lactams, Cyclic Lipopeptides, Fluoroquinolones, Glycopeptides, Glycylcyclines, Lipoglycopeptides, and Oxazolidinones.

 

Beta lactams are bactericidal in action and are administered parenterally. At the same time, cyclic lipopeptides are broad-spectrum antibiotics exhibiting concentration dependant bactericidal activity and have reversible side effects on discontinuation of treatment.

 

Fluoroquinolones are used in treating acute bacterial skin and skin structure infections and consist of quinolones, making them active in an acidic environment and can be administered by both oral and parenteral routes.

 

Glycopeptides, another class of antibiotics, possess bactericidal action against gram-positive and gram-negative bacteria, while glycylcyclines are a broad-spectrum intravenous class exhibiting action against atypical, anaerobic, gram-positive, gram-negative and few multidrug-resistant pathogens.

 

Oxazolidinones and lipoglycopeptides act only on gram-positive pathogens and are available in oral and intravenous forms.

 

Of all the available antibiotics classes, Cephalosporins account for a significant share of the acute bacterial skin and skin structure infections treatment market, followed by Penicillin, Quinolones, Clindamycin, and Tetracyclines.

 

Patients suffering from acute bacterial skin and skin structure infections opt for hospital visits, ambulatory services, or emergency department visits. The patients can be treated both as inpatients and outpatients. Inpatient care requires the patient to stay in the hospital while outpatient care does not demand any hospital stay.

 

Alternative Management Options in the Acute Bacterial Skin and Skin Structure Infections Treatment Market

The primary aim of healthcare professionals is to minimise inpatient stays and hospital admissions. Generally, patients with symptoms like lack of aggravation of comorbidities, no signs of sepsis, and low suspicion are manageable as outpatients.

 

A surgical procedure is another treatment option for acute bacterial skin and skin structure infections. During the surgery, the doctors aim to remove all the foreign agents and drain the infected fluids, thus helping in the eradication ABSSSIs.

 

The management of acute bacterial skin and skin structure infections is based on two critical objectives: early switch therapy and early discharge.

 

In early switch therapy, physicians generally aim to switch patients from intravenous to oral route, while in early discharge treatment, the main objective of the physician is to complete the entire treatment after hospital discharge.

 

Scientists have also discovered some outpatients’ parenteral antimicrobial therapy, which recommends selecting and observing patients and applying antimicrobial treatment in community settings.

 

Through the acute bacterial skin and skin structure infections treatment market analysis, it was demonstrated that a specific population across the world is more susceptible to these infections than others. This specific population includes elderly people and patients with other co-morbidities like renal impairment, immunosuppression, and cardiovascular diseases. Thus, an increase in this population also drives the growth of the acute bacterial skin and skin structure infections treatment market.

 

Clinical Trial Landscape

The Food and Drug Administration works endlessly on clinical trials and programs for acute bacterial skin and skin structure infections. According to the new FDA guidelines, the central ideology behind the clinical trials of ABSSSIs drugs and therapy is the application of an active comparator antibacterial drug and medication.

 

Scientists are working on several clinical trials, which will be accessible in the acute bacterial skin and skin structure treatment market in the coming years.

 

  • Basilea Pharmaceutica Ltd. has recently announced the successful completion of the Phase III study in patients with Staphylococcus aureus bacteremia.
  • A new drug possessing the inhibiting action of bacterial hydro folate reductase is also being clinically tested and can soon be used to treat ABSSSIs.
  • Another novel drug, non-peptide by chemical nature, seems promising for treating acute bacterial skin and skin structure infections by depolarising bacterial membranes.
  • An agent of the pleuromutilin class inhibits bacterial protein synthesis and has successfully passed Phase II clinical trials.
  • New class of antibiotics responsible for the bacterial fatty acid biosynthesis acts by blocking the action of the FabI enzyme.
  • Novel fluoroquinolones exhibiting bactericidal activity are also evaluated for treating acute bacterial skin and skin structure infections.
  • Oxazolidinones are evaluated in the Phase II trials for patients suffering from acute skin and skin structure infections.
  • Hybrid rifamycin-quinolone antibiotic, acting on gram-positive bacteria, is also helpful for the ABSSSIs treatment.
  • Novel glycopeptide cephalosporin agents also exhibit bactericidal activity and thus can be beneficial for ABSSSIs treatment.
  • New drug agents belonging to the triazaacenaphthylene antibacterials were also being studied in Phase II trials. Further evaluation is needed to know the exact role of this novel agent in treating ABSSSIs.
  • A bacteriophage encoded peptidoglycan hydrolase is also being found effective for this infection and is still under evaluation.
  • A monoclonal antibody possessing potent bactericidal action and is under in vitro studies.

 

Scientists are also developing new drugs and medications that are antibiotic resistant and have potent action. Several ongoing clinical trials are emerging as a growth driving factor for the acute bacterial skin and skin structure infections treatment market.

 

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the market, sponsors manufacturing the drugs, putting them through trials to get FDA approvals. The acute bacterial skin and skin structure infections treatment companies included in the market are as follows :

 

  • Paratek Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Melinta Therapeutics
  • AbbVie Inc.
  • Sandoz International GmbH
  • Glenmark Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Limited
  • Aceragen, Inc. (Arrevus, Inc.)
  • Accord Healthcare
  • Intas Pharmaceuticals
  • Fresenius SE & Co. KGaA
  • Zydus Lifesciences Limited

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2022
Historical Period 2016-2022
Forecast Period 2023-2031
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Infection Type
  • Route of Administration
  • Treatment Channel
  • Region
Breakup by Infection Type
  • Hospital Acquired 
  • Community Acquired
  • Others
Breakup by Route of Administration
  • Oral 
  • Parenteral
  • Topical
  • Others
Breakup by Treatment Channel
  • Public
  • Private
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Paratek Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Melinta Therapeutics
  • AbbVie Inc.
  • Sandoz International GmbH
  • Glenmark Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Limited
  • Aceragen, Inc. (Arrevus, Inc.)
  • Intas Pharmaceuticals 
  • Fresenius SE & Co. KGaA
  • Zydus Lifesciences Limited

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
        1.1.1    Research Objectives
        1.1.2    Key Findings of the Report
    1.2    Limitations of the Study and Scope for Future Research
2    Research Methodology
3    Executive Summary
4    Global Acute Bacterial Skin and Skin Structure Infections Overview

    4.1    Guidelines and Stages
    4.2    Pathophysiology
    4.3    Screening and Diagnosis
    4.4    Treatment Pathway 
5    Patient Profile
    5.1    Patient Profile Overview
    5.2    Patient Psychology and Emotional Impact Factors
    5.3    Risk Assessment and Treatment Success Rate
6    Global Acute Bacterial Skin and Skin Structure Infections Treatment Market 
    6.1    Global Acute Bacterial Skin and Skin Structure Infections Treatment Market Overview
    6.2    Global Acute Bacterial Skin and Skin Structure Infections Treatment Market Analysis 
        6.2.1    Market Overview
        6.2.1.1    Global Acute Bacterial Skin and Skin Structure Infections Treatment Market Historical Value (2016-2022) 
        6.2.1.2    Global Acute Bacterial Skin and Skin Structure Infections Treatment Market Forecast Value (2023-2031)
    6.3    Global Acute Bacterial Skin and Skin Structure Infections Treatment Market by Infection Type
        6.3.1    Market Overview
        6.3.1.1    Hospital Acquired 
        6.3.1.2    Community Acquired
        6.3.1.3    Others
    6.4    Global Acute Bacterial Skin and Skin Structure Infections Treatment Market by Route of Administration
        6.4.1    Market Overview
        6.4.1.1    Oral 
        6.4.1.2    Parenteral
        6.4.1.3    Topical
        6.4.1.4    Others
    6.5    Global Acute Bacterial Skin and Skin Structure Infections Treatment Market by Treatment Channel
        6.5.1    Market Overview
        6.5.1.1    Public
        6.5.1.2    Private
    6.6    Global Acute Bacterial Skin and Skin Structure Infections Treatment Market by Region
        6.6.1    Market Overview
            6.6.1.1    North America
            6.6.1.2    Europe 
            6.6.1.3    Asia Pacific
            6.6.1.4    Latin America
            6.6.1.5    Middle East and Africa
        6.6.2    North America
            6.6.2.1    Historical Trend (2016-2022)
            6.6.2.2    Forecast Trend (2023-2031)
            6.6.2.3    Break Up by Country
                6.6.2.3.1    United States of America
                6.6.2.3.2    Canada
        6.6.3    Europe
            6.6.3.1    Historical Trend (2016-2022)
            6.6.3.2    Forecast Trend (2023-2031)
            6.6.3.3    Break Up by Country
                6.6.3.3.1    United Kingdom
                6.6.3.3.2    Germany
                6.6.3.3.3    France
                6.6.3.3.4    Italy
                6.6.3.3.5    Others
        6.6.4    Asia Pacific
            6.6.4.1    Historical Trend (2016-2022)
            6.6.4.2    Forecast Trend (2023-2031)
            6.6.4.3    Break Up by Country
                6.6.4.3.1    China
                6.6.4.3.2    Japan
                6.6.4.3.3    India
                6.6.4.3.4    ASEAN
                6.6.4.3.5    Australia
                6.6.4.3.6    Others
        6.6.5    Latin America
            6.6.5.1    Historical Trend (2016-2022)
            6.6.5.2    Forecast Trend (2023-2031)
            6.6.5.3    Break Up by Country
                6.6.5.3.1    Brazil
                6.6.5.3.2    Argentina
                6.6.5.3.3    Mexico
                6.6.5.3.4    Others
        6.6.6    Middle East and Africa
            6.6.6.1    Historical Trend (2016-2022)
            6.6.6.2    Forecast Trend (2023-2031)
            6.6.6.3    Break Up by Country
                6.6.6.3.1    Saudi Arabia
                6.6.6.3.2    United Arab Emirates
                6.6.6.3.3    Nigeria
                6.6.6.3.4    South Africa
                6.6.6.3.5    Others
7    Current Scenario Evaluation and Regulatory Framework
    7.1    Emerging Therapies and Clinical Trials
    7.2    Patent Landscape 
        7.2.1    Patent Overview
            7.2.1.1    Patent Status and Expiry
            7.2.1.2    Timelines from Drug Development to Commercial Launch
            7.2.1.3    New Drug Application
                7.2.1.3.1    Documentation and Approval Process
    7.3    Cost of Treatment
    7.4    Regulatory Framework
        7.4.1    Regulatory Overview
            7.4.1.1    US FDA
            7.4.1.2    EU EMA
            7.4.1.3    INDIA CDSCO
            7.4.1.4    JAPAN PMDA
            7.4.1.5    Others
8    Challenges & Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Global Acute Bacterial Skin and Skin Structure Infections Treatment Market Dynamics
    9.1    Market Drivers and Constraints
    9.2    SWOT Analysis
    9.3    Porter’s Five Forces Model 
    9.4    Key Demand Indicators 
    9.5    Key Price Indicators 
    9.6    Industry Events, Initiatives & Trends
    9.7    Value Chain Analysis
10    Supplier Landscape
    10.1    Paratek Pharmaceuticals, Inc.
        10.1.1    Company Overview
        10.1.2    Product Portfolio
        10.1.3    Demographic Reach and Achievements
        10.1.4    Mergers and Acquisitions
        10.1.5    Certifications
    10.2    Merck & Co., Inc.
        10.2.1    Company Overview
        10.2.2    Product Portfolio
        10.2.3    Demographic Reach and Achievements
        10.2.4    Mergers and Acquisitions
        10.2.5    Certifications
    10.3    Melinta Therapeutics
        10.3.1    Company Overview
        10.3.2    Product Portfolio
        10.3.3    Demographic Reach and Achievements
        10.3.4    Mergers and Acquisitions
        10.3.5    Certifications
    10.4    AbbVie Inc.
        10.4.1    Company Overview
        10.4.2    Product Portfolio
        10.4.3    Demographic Reach and Achievements
        10.4.4    Mergers and Acquisitions
        10.4.5    Certifications
    10.5    Sandoz International GmbH
        10.5.1    Company Overview
        10.5.2    Product Portfolio
        10.5.3    Demographic Reach and Achievements
        10.5.4    Mergers and Acquisitions
        10.5.5    Certifications
    10.6    Glenmark Pharmaceuticals Ltd.
        10.6.1    Company Overview
        10.6.2    Product Portfolio
        10.6.3    Demographic Reach and Achievements
        10.6.4    Mergers and Acquisitions
        10.6.5    Certifications
    10.7    Teva Pharmaceutical Industries Ltd.
        10.7.1    Company Overview
        10.7.2    Product Portfolio
        10.7.3    Demographic Reach and Achievements
        10.7.4    Mergers and Acquisitions
        10.7.5    Certifications
    10.8    Sun Pharmaceutical Industries Limited
        10.8.1    Company Overview
        10.8.2    Product Portfolio
        10.8.3    Demographic Reach and Achievements
        10.8.4    Mergers and Acquisitions
        10.8.5    Certifications
    10.9    Aceragen, Inc. (Arrevus, Inc.)
        10.9.1    Company Overview
        10.9.2    Product Portfolio
        10.9.3    Demographic Reach and Achievements
        10.9.4    Mergers and Acquisitions
        10.9.5    Certifications
    10.10    Intas Pharmaceuticals 
        10.10.1    Company Overview
        10.10.2    Product Portfolio
        10.10.3    Demographic Reach and Achievements
        10.10.4    Mergers and Acquisitions
        10.10.5    Certifications
    10.11    Fresenius SE & Co. KGaA
        10.11.1    Company Overview
        10.11.2    Product Portfolio
        10.11.3    Demographic Reach and Achievements
        10.11.4    Mergers and Acquisitions
        10.11.5    Certifications
    10.12    Zydus Lifesciences Limited
        10.12.1    Company Overview
        10.12.2    Product Portfolio
        10.12.3    Demographic Reach and Achievements
        10.12.4    Mergers and Acquisitions
        10.12.5    Certifications
11    Recommendations and Discussion
12    Global Acute Bacterial Skin and Skin Structure Infections Treatment Drugs Distribution Model (Additional Insight)

    12.1    Overview 
    12.2    Potential Distributors 
    12.3    Key Parameters for Distribution Partner Assessment 
13    Payment Methods (Additional Insight)
    13.1    Government Funded
    13.2    Private Insurance
    13.3    Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

Based on the infection type, the market is divided into hospital acquired and community acquired.

Based on the route of administration, the market is divided into oral, topical, and parenteral, among others.

The treatment channels in this market can be divided into private and public.

The United States of America accounts for the maximum share owing to the higher prevalence of skin and skin structure infections.

First-generation cephalosporins are the most effective antibiotics for treating ABSSSIs.

The two most common bacteria in skin infections are Streptococcus pyogenes and Staphylococcus aureus.

Acute bacterial skin and skin structure infection is an infection of the skin and associated tissues caused by bacteria. It can be treated with the help of antibiotics.

Antibiotic resistance is the limiting factor which hampers the treatment market growth.

The different categories of antibiotics used for treating ABSSSIs are Beta Lactams, Cyclic Lipopeptides, Fluoroquinolones, Glycopeptides, Glycylcyclines, Lipoglycopeptides, and Oxazolidinones.

These infections are often treated with antibiotics. If the strain of the bacteria is resistant to treatment, surgical intervention may be required.

Dalvance is the latest approved drug by USFDA for the treatment of SABS and ABSSSIs.

The key companies involved in the ABSSSIs market are Paratek Pharmaceuticals, Inc., Merck & Co., Inc., Melinta Therapeutics, AbbVie Inc., Sandoz International GmbH, Glenmark Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Aceragen, Inc. (Arrevus, Inc.), Accord Healthcare, Intas Pharmaceuticals, Fresenius SE & Co. KGaA, and Zydus Lifesciences Limited, among others.

Purchase Full Report

Mini Report

$2499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$6499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$7999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER